XRCC2 and neoplasm: The expression of XRCC2 and PARP1 in biopsy tumor specimens collected from 167 LARC patients before treatment with neoCRT followed by surgery indicated that 57 samples (34.1%) were XRCC2+ and 52 samples (31.1%) were PARP1+ (Fig. 1A).